TNG462
Sponsors
Tango Therapeutics Inc., Tango Therapeutics Inc., Institut De Recherches Internationales Servier IRIS, Tango Therapeutics, Inc., Servier Bio-Innovation LLC
Conditions
Locally Advanced Solid TumorLung CancerMTAP DeletionMTAP-deleted Advanced or Metastatic Solid TumorsMTAP-deleted Solid TumorsMTAP-deleted advanced or metastatic solid tumorsNSCLCPDAC
Phase 1
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
RecruitingNCT05732831
Start: 2023-05-26End: 2026-09-30Target: 225Updated: 2025-11-14
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
RecruitingCTIS2022-502645-99-00
Start: 2023-08-09Target: 70Updated: 2025-11-27
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
RecruitingNCT06188702
Start: 2024-04-29End: 2031-10-31Target: 342Updated: 2026-04-03
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RecruitingNCT06922591
Start: 2025-05-31End: 2027-12-31Target: 183Updated: 2025-12-11
A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
RecruitingCTIS2025-521249-25-00
Start: 2025-10-30Target: 118Updated: 2025-10-01